Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on April 10, 2025
TYG Training Launches First Canadian Location in Whitby, Bringing Community-Driven Fitness to Durham Region
GlobeNewswire
·
April 10, 2025
WHITBY, Ontario, April 10, 2025 (GLOBE NEWSWIRE) -- TYG Training (TYG) has officially opened its first Canadian location in Whitby at 910 Dundas St W, Unit 104 — a boutique strength and conditioning club designed for all fitness levels and age groups (16 …
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
GlobeNewswire
·
April 10, 2025
- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease’s serious cardiovascular and musculoskeletal complications - - Findings highlight the urgent need for early and improved diagnosis, care …
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
GlobeNewswire
·
April 10, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announced that its Board of Directors has authorized a share repurchase program under which the …
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
GlobeNewswire
·
April 10, 2025
Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancers Pluri’s MAIT platform enables commercial scale production of powerful immune cells as a potential first-in- …
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
GlobeNewswire
·
April 10, 2025
Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Love with Boundaries Publishes New Blog on "How to Love an Addict Without Losing Yourself"
EIN Presswire
·
April 10, 2025
Love With Boundaries announces supportive resources and new programs coming soon. VANCOUVER, BC, CANADA, April 9, 2025 /EINPresswire.com/ -- When someone you love is struggling with addiction, it’s easy to get swept into the chaos—losing sleep, walking …
VitalHub Announces Recommended Cash Acquisition of Induction Healthcare Group PLC
GlobeNewswire
·
April 10, 2025
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX: VHIBF) is pleased to announce that it has agreed the terms and conditions of a recommended cash acquisition to acquire all of the issued and to be …
Evaxion to present at World Vaccine Congress
GlobeNewswire
·
April 10, 2025
Congress will take place April 21-24, 2025, in Washington, D.C. COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two …
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
GlobeNewswire
·
April 10, 2025
DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites …
Avalyn to Participate in Upcoming Investor Conference in April
GlobeNewswire
·
April 10, 2025
CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced that management will …
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO
GlobeNewswire
·
April 10, 2025
– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA Capital Management and SV Health Investors – – Proceeds to support advancement of ninerafaxstat for the …
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
GlobeNewswire
·
April 10, 2025
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy …
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
GlobeNewswire
·
April 10, 2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need …
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
GlobeNewswire
·
April 10, 2025
– Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering therapy – – Findings from a patient survey conducted in partnership with the National …
Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases
GlobeNewswire
·
April 10, 2025
Northstrive Biosciences and Yuva Biosciences’ collaboration will leverage MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes …
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors
GlobeNewswire
·
April 10, 2025
Dansey, a former senior executive at Pfizer and Seagen, Inc., brings extensive experience in immuno-oncology and drug development Board appointment reinforces Company’s commitment to advancing Jankistomig, a one-of-a-kind PD-1/VEGFR2 dual paratopic …
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer
GlobeNewswire
·
April 10, 2025
Advanced BVA System Designed for Faster, Simpler Bedside Testing Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announces today the submission of its next-generation blood …
Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China
GlobeNewswire
·
April 10, 2025
FREEHOLD, N.J., April 10, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has been …
Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
GlobeNewswire
·
April 10, 2025
A$5.0 million commitment received from Australian-based private investor A$10.8 million Entitlement Offer at the same offer price as the placement Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026 …
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
GlobeNewswire
·
April 10, 2025
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target for drugs both effecting cancer cells and blocking …